INMED PHARMACEUTICALS INC. Unrealized Gain (Loss) on Derivatives
INMED PHARMACEUTICALS INC. (INM) reported Unrealized Gain (Loss) on Derivatives of $242.63 thousand for the 12-month period ending 2021-06-30, per its 10-K filed 2022-09-23.
Discontinued › Cash Flow › Operating Activities
us-gaap:UnrealizedGainLossOnDerivatives · last filed 2022-09-23
- INMED PHARMACEUTICALS INC. unrealized gain (loss) on derivatives for the quarter ending 2021-06-30 was $0.00.
- INMED PHARMACEUTICALS INC. unrealized gain (loss) on derivatives for the quarter ending 2021-03-31 was $0.00.
- INMED PHARMACEUTICALS INC. unrealized gain (loss) on derivatives for the quarter ending 2020-12-31 was $242.63K.
- INMED PHARMACEUTICALS INC. unrealized gain (loss) on derivatives for fiscal 2021 was $242.63K.
| Period end | Unrealized Gain (Loss) on Derivatives 3 month | Unrealized Gain (Loss) on Derivatives 6 month | Unrealized Gain (Loss) on Derivatives 6 month as first filed | Unrealized Gain (Loss) on Derivatives 9 month | Unrealized Gain (Loss) on Derivatives 9 month as first filed | Unrealized Gain (Loss) on Derivatives 12 month |
|---|---|---|---|---|---|---|
| 2021-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-23 | $0.00 derived: sum of 2 quarters · filed 2022-09-23 | $242.63K derived: sum of 3 quarters · filed 2022-09-23 | $242.63K 10-K · filed 2022-09-23 | ||
| 2021-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-13 | $242.63K derived: sum of 2 quarters · filed 2022-05-13 | $242.63K 10-Q · filed 2022-05-13 | -$242.63K 10-Q · filed 2021-05-13 | ||
| 2020-12-31 | $242.63K 10-Q · filed 2022-02-14 | $242.63K 10-Q · filed 2022-02-14 | -$242.63K 10-Q · filed 2021-02-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |